Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
157 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Diabetic Foot Ulcers - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Foot Ulcers - Pipeline Review, H2 2016, provides an overview of the Diabetic Foot Ulcers (Metabolic Disorders) pipeline landscape. Diabetic foot ulcers are sores that occur on the feet of people with Type 1 Diabetes and Type 2 Diabetes. Symptoms include sores, ulcers, or blisters on the foot or lower leg, pain, walking with difficulty, discoloration in feet: black, blue, or red, cold feet and fever, skin redness or swelling, or other signs of infection. The predisposing factors include diabetic neuropathy, peripheral vascular disease, a foot deformity and history of tobacco use disorder. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Foot Ulcers - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 16, 5, 16, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Diabetic Foot Ulcers. Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers (Metabolic Disorders). - The pipeline guide reviews pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Diabetic Foot Ulcers (Metabolic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Diabetic Foot Ulcers (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Diabetic Foot Ulcers (Metabolic Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 7 Global Markets Direct Report Coverage 7 Diabetic Foot Ulcers Overview 8 Therapeutics Development 9 Pipeline Products for Diabetic Foot Ulcers - Overview 9 Pipeline Products for Diabetic Foot Ulcers - Comparative Analysis 10 Diabetic Foot Ulcers - Therapeutics under Development by Companies 11 Diabetic Foot Ulcers - Therapeutics under Investigation by Universities/Institutes 13 Diabetic Foot Ulcers - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Unknown Stage Products 17 Diabetic Foot Ulcers - Products under Development by Companies 18 Diabetic Foot Ulcers - Products under Investigation by Universities/Institutes 21 Diabetic Foot Ulcers - Companies Involved in Therapeutics Development 22 ANP Technologies Inc 22 CardioVascular BioTherapeutics Inc 23 Celgene Corp 24 Chrysalis BioTherapeutics Inc 25 CytoTools AG 26 EyeGene Inc 27 FirstString Research Inc 28 Genentech Inc 29 GlaxoSmithKline Plc 30 Human Stem Cells Institute 31 Izun Pharmaceuticals Corp 32 Karyopharm Therapeutics Inc 33 Lakewood-Amedex Inc 34 Lytix Biopharma AS 35 Mallinckrodt Plc 36 MediWound Ltd 37 NovaLead Pharma Pvt Ltd 38 Oneness Biotech Co Ltd 39 Osiris Therapeutics Inc 40 Pherecydes Pharma SA 41 Plurogen Therapeutics Inc 42 TechnoPhage SA 43 TGV-Laboratories 44 Theravasc Inc 45 Topadur Pharma AG 46 USV Pvt Ltd 47 viDA Therapeutics Inc 48 ViroMed Co Ltd 49 Diabetic Foot Ulcers - Therapeutics Assessment 50 Assessment by Monotherapy Products 50 Assessment by Target 51 Assessment by Mechanism of Action 53 Assessment by Route of Administration 55 Assessment by Molecule Type 57 Drug Profiles 59 3K3A-APC - Drug Profile 59 ALLO-ASC - Drug Profile 61 ANP-017 - Drug Profile 62 AP-102 - Drug Profile 63 APO-2 - Drug Profile 64 becaplermin biosimilar - Drug Profile 65 Cell Therapy to Activate Cathelicidin for Diabetic Foot Ulcers and Crural Ulcer - Drug Profile 66 Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug Profile 68 CL-05 - Drug Profile 69 CODA-001 - Drug Profile 72 CVBT-141B - Drug Profile 74 Cyndacel-M - Drug Profile 75 daprodustat - Drug Profile 76 EG-Decorin - Drug Profile 78 epidermal growth factor biosimilar - Drug Profile 79 EscharEx - Drug Profile 80 esmolol hydrochloride - Drug Profile 82 Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile 83 Granexin - Drug Profile 84 Heberprot-P - Drug Profile 86 IMSP-001 - Drug Profile 87 IZN-6D4 - Drug Profile 88 LTX-109 - Drug Profile 89 MT-003 - Drug Profile 91 Mul-1867 - Drug Profile 92 Neovasculgen - Drug Profile 93 Nu-2 - Drug Profile 94 Nu-3 - Drug Profile 95 ON-101 - Drug Profile 97 OTI-1501 - Drug Profile 99 PDA-002 - Drug Profile 100 PluroGel N - Drug Profile 101 PP-2351 - Drug Profile 102 Recombinant Protein for Wounds, Bone Regeneration and Diabetic Ulcers - Drug Profile 103 RG-7880 - Drug Profile 104 rusalatide acetate - Drug Profile 105 selinexor - Drug Profile 108 sodium nitrite SR - Drug Profile 127 Stathmin-1 - Drug Profile 129 TOPN-53 - Drug Profile 130 TP-102 - Drug Profile 131 V-10 - Drug Profile 132 VM-202 - Drug Profile 133 VTI-1000 Series - Drug Profile 137 VTI-3000 Series - Drug Profile 138 Diabetic Foot Ulcers - Dormant Projects 139 Diabetic Foot Ulcers - Discontinued Products 143 Diabetic Foot Ulcers - Product Development Milestones 144 Featured News & Press Releases 144 Appendix 153 Methodology 153 Coverage 153 Secondary Research 153 Primary Research 153 Expert Panel Validation 153 Contact Us 153 Disclaimer 154
List of Tables
Number of Products under Development for Diabetic Foot Ulcers, H2 2016 12 Number of Products under Development for Diabetic Foot Ulcers - Comparative Analysis, H2 2016 13 Number of Products under Development by Companies, H2 2016 14 Number of Products under Development by Companies, H2 2016 (Contd..1) 15 Number of Products under Investigation by Universities/Institutes, H2 2016 16 Comparative Analysis by Late Stage Development, H2 2016 17 Comparative Analysis by Clinical Stage Development, H2 2016 18 Comparative Analysis by Early Stage Development, H2 2016 19 Comparative Analysis by Unknown Stage Development, H2 2016 20 Products under Development by Companies, H2 2016 21 Products under Development by Companies, H2 2016 (Contd..1) 22 Products under Development by Companies, H2 2016 (Contd..2) 23 Products under Investigation by Universities/Institutes, H2 2016 24 Diabetic Foot Ulcers - Pipeline by ANP Technologies Inc, H2 2016 25 Diabetic Foot Ulcers - Pipeline by CardioVascular BioTherapeutics Inc, H2 2016 26 Diabetic Foot Ulcers - Pipeline by Celgene Corp, H2 2016 27 Diabetic Foot Ulcers - Pipeline by Chrysalis BioTherapeutics Inc, H2 2016 28 Diabetic Foot Ulcers - Pipeline by CytoTools AG, H2 2016 29 Diabetic Foot Ulcers - Pipeline by EyeGene Inc, H2 2016 30 Diabetic Foot Ulcers - Pipeline by FirstString Research Inc, H2 2016 31 Diabetic Foot Ulcers - Pipeline by Genentech Inc, H2 2016 32 Diabetic Foot Ulcers - Pipeline by GlaxoSmithKline Plc, H2 2016 33 Diabetic Foot Ulcers - Pipeline by Human Stem Cells Institute, H2 2016 34 Diabetic Foot Ulcers - Pipeline by Izun Pharmaceuticals Corp, H2 2016 35 Diabetic Foot Ulcers - Pipeline by Karyopharm Therapeutics Inc, H2 2016 36 Diabetic Foot Ulcers - Pipeline by Lakewood-Amedex Inc, H2 2016 37 Diabetic Foot Ulcers - Pipeline by Lytix Biopharma AS, H2 2016 38 Diabetic Foot Ulcers - Pipeline by Mallinckrodt Plc, H2 2016 39 Diabetic Foot Ulcers - Pipeline by MediWound Ltd, H2 2016 40 Diabetic Foot Ulcers - Pipeline by NovaLead Pharma Pvt Ltd, H2 2016 41 Diabetic Foot Ulcers - Pipeline by Oneness Biotech Co Ltd, H2 2016 42 Diabetic Foot Ulcers - Pipeline by Osiris Therapeutics Inc, H2 2016 43 Diabetic Foot Ulcers - Pipeline by Pherecydes Pharma SA, H2 2016 44 Diabetic Foot Ulcers - Pipeline by Plurogen Therapeutics Inc, H2 2016 45 Diabetic Foot Ulcers - Pipeline by TechnoPhage SA, H2 2016 46 Diabetic Foot Ulcers - Pipeline by TGV-Laboratories, H2 2016 47 Diabetic Foot Ulcers - Pipeline by Theravasc Inc, H2 2016 48 Diabetic Foot Ulcers - Pipeline by Topadur Pharma AG, H2 2016 49 Diabetic Foot Ulcers - Pipeline by USV Pvt Ltd, H2 2016 50 Diabetic Foot Ulcers - Pipeline by viDA Therapeutics Inc, H2 2016 51 Diabetic Foot Ulcers - Pipeline by ViroMed Co Ltd, H2 2016 52 Assessment by Monotherapy Products, H2 2016 53 Number of Products by Stage and Target, H2 2016 55 Number of Products by Stage and Mechanism of Action, H2 2016 57 Number of Products by Stage and Route of Administration, H2 2016 59 Number of Products by Stage and Molecule Type, H2 2016 61 Diabetic Foot Ulcers - Dormant Projects, H2 2016 142 Diabetic Foot Ulcers - Dormant Projects (Contd..1), H2 2016 143 Diabetic Foot Ulcers - Dormant Projects (Contd..2), H2 2016 144 Diabetic Foot Ulcers - Dormant Projects (Contd..3), H2 2016 145 Diabetic Foot Ulcers - Discontinued Products, H2 2016 146
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
